These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34817831)

  • 1. Naloxone and nalmefene absorption delivered by hollow microneedles compared to intramuscular injection.
    Papich MG; Narayan RJ
    Drug Deliv Transl Res; 2022 Feb; 12(2):376-383. PubMed ID: 34817831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose.
    Krieter P; Gyaw S; Crystal R; Skolnick P
    J Pharmacol Exp Ther; 2019 Nov; 371(2):409-415. PubMed ID: 30940694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system.
    Kim S; Wagner HN; Villemagne VL; Kao PF; Dannals RF; Ravert HT; Joh T; Dixon RB; Civelek AC
    J Nucl Med; 1997 Nov; 38(11):1726-31. PubMed ID: 9374341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of opioid antagonism by nalmefene and naloxone in the dog. A nonparametric pharmacodynamic comparison based on generalized cross-validated spline estimation.
    Wilhelm JA; Veng-Pedersen P; Zakszewski TB; Osifchin E; Waters SJ
    Int J Clin Pharmacol Ther; 1995 Oct; 33(10):540-5. PubMed ID: 8574503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of Opioid-Induced Respiratory Depression in Healthy Volunteers: Comparison of Intranasal Nalmefene and Intranasal Naloxone.
    Ellison M; Hutton E; Webster L; Skolnick P
    J Clin Pharmacol; 2024 Jul; 64(7):828-839. PubMed ID: 38436495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic Properties of an FDA-approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose.
    Crystal R; Ellison M; Purdon C; Skolnick P
    Clin Pharmacol Drug Dev; 2024 Jan; 13(1):58-69. PubMed ID: 37496452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of opioid antagonism by nalmefene and naloxone in the dog: an integrated pharmacokinetic/pharmacodynamic comparison.
    Veng-Pedersen P; Wilhelm JA; Zakszewski TB; Osifchin E; Waters SJ
    J Pharm Sci; 1995 Sep; 84(9):1101-6. PubMed ID: 8537889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose.
    Kaplan JL; Marx JA; Calabro JJ; Gin-Shaw SL; Spiller JD; Spivey WL; Gaddis GM; Zhao N; Harchelroad FP
    Ann Emerg Med; 1999 Jul; 34(1):42-50. PubMed ID: 10381993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipophilic nalmefene prodrugs to achieve a one-month sustained release.
    Gaekens T; Guillaume M; Borghys H; De Zwart LL; de Vries R; Embrechts RC; Vermeulen A; Megens AA; Leysen JE; Herdewijn P; Annaert PP; Atack JR
    J Control Release; 2016 Jun; 232():196-202. PubMed ID: 27107723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of intranasal naloxone and intranasal nalmefene in a translational model assessing the impact of synthetic opioid overdose on respiratory depression and cardiac arrest.
    Laffont CM; Purohit P; Delcamp N; Gonzalez-Garcia I; Skolnick P
    Front Psychiatry; 2024; 15():1399803. PubMed ID: 38952632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition of the opioid antagonist, nalmefene, in rat and dog.
    Murthy SS; Mathur C; Kvalo LT; Lessor RA; Wilhelm JA
    Xenobiotica; 1996 Jul; 26(7):779-92. PubMed ID: 8819305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism.
    Schluger JH; Ho A; Borg L; Porter M; Maniar S; Gunduz M; Perret G; King A; Kreek MJ
    Alcohol Clin Exp Res; 1998 Oct; 22(7):1430-6. PubMed ID: 9802524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo characterization of the opioid antagonist nalmefene in mice.
    Osborn MD; Lowery JJ; Skorput AG; Giuvelis D; Bilsky EJ
    Life Sci; 2010 Apr; 86(15-16):624-30. PubMed ID: 20159022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nalmefene reverses carfentanil-induced loss of righting reflex and respiratory depression in rats.
    Yong Z; Gao X; Ma W; Dong H; Gong Z; Su R
    Eur J Pharmacol; 2014 Sep; 738():153-7. PubMed ID: 24886878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study.
    McDonald R; Lorch U; Woodward J; Bosse B; Dooner H; Mundin G; Smith K; Strang J
    Addiction; 2018 Mar; 113(3):484-493. PubMed ID: 29143400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial.
    Skulberg AK; Åsberg A; Khiabani HZ; Røstad H; Tylleskar I; Dale O
    Addiction; 2019 May; 114(5):859-867. PubMed ID: 30644628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics of 6beta-naltrexol after single and multiple intramuscular injections in Beagle dogs].
    Yan LD; Liu J; Dong HJ; Cui MX; Yao XJ; Liu YS; Gong ZH; Gong ZH
    Yao Xue Xue Bao; 2009 Jul; 44(7):722-5. PubMed ID: 19806909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nalmefene: radioimmunoassay for a new opioid antagonist.
    Dixon R; Hsiao J; Taaffe W; Hahn E; Tuttle R
    J Pharm Sci; 1984 Nov; 73(11):1645-6. PubMed ID: 6520774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine.
    Wang DS; Sternbach G; Varon J
    J Emerg Med; 1998; 16(3):471-5. PubMed ID: 9610980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nalmefene: quantitation of a new narcotic antagonist in human plasma using high performance-liquid chromatography with electrochemical detection.
    Hsiao J; Dixon R
    Res Commun Chem Pathol Pharmacol; 1983 Dec; 42(3):449-54. PubMed ID: 6665302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.